viruslik
particl
vlp
nanostructur
resembl
structur
virus
compos
one
structur
protein
arrang
sever
layer
also
contain
lipid
outer
envelop
vlp
trigger
high
humor
cellular
immun
respons
due
repetit
structur
key
factor
regard
vlp
safeti
lack
viral
genom
materi
enhanc
safeti
manufactur
administr
contemporari
vlp
product
may
take
advantag
sever
system
includ
bacteri
yeast
insect
mammalian
cell
choic
product
platform
depend
sever
factor
includ
cost
need
posttransl
modif
ptm
essenti
gener
optim
immun
respons
vlpbase
vaccin
design
prevent
sever
infecti
diseas
alreadi
approv
market
mani
other
clinic
trial
research
stage
interest
technolog
recent
increas
due
advantag
classic
vaccin
paper
review
stateoftheart
vlp
product
system
newest
gener
vlpbase
vaccin
avail
vast
major
prevent
viral
vaccin
consist
attenu
inactiv
viru
administr
individu
provok
protect
immun
respons
type
vaccin
effect
gener
second
administr
use
adjuv
requir
nevertheless
attenu
vaccin
particular
present
risk
level
manufactur
administr
sinc
principl
revert
pathogen
form
newer
gener
vaccin
improv
safeti
remov
whole
virus
formul
altogeth
instead
util
protein
subunit
dna
viruslik
particl
vlp
fig
subunit
vaccin
compos
recombin
viral
protein
purifi
protein
wildtyp
viru
act
antigen
dna
vaccin
techniqu
consist
direct
administr
recipi
plasmid
dna
encod
antigen
protein
express
recipi
cell
subsequ
gener
immun
respons
viruslik
particl
artifici
nanostructur
resembl
viru
compos
protein
form
viral
capsid
lack
genom
materi
preclud
possibl
revers
mutat
pathogen
infect
vlp
unabl
replic
recipi
stimul
immun
system
recognit
repetit
subunit
produc
high
cellular
humor
immun
respons
due
advantag
compar
type
vaccin
interest
vlp
technolog
increas
recent
year
fig
viruslik
particl
compos
one
sever
structur
protein
abil
selfassembl
recombinantli
express
protein
arrang
singl
doubl
tripl
layer
case
human
papillomaviru
hpv
vlp
form
singl
structur
protein
form
basic
capsid
particl
complex
vlp
compris
sever
structur
protein
eg
vlp
reovirida
famili
form
differ
protein
dispos
sever
layer
vlp
also
extern
lipid
envelop
case
structur
protein
core
exit
cell
bud
process
envelop
capsid
within
part
cell
membran
case
vlp
form
gag
polyprotein
take
part
host
cell
membran
envelop
influenza
vlp
also
form
protein
core
hemagglutinin
spike
abbrevi
vlp
viruslik
particl
bic
baculovirusinsect
cell
express
system
display
surfac
henc
choic
produc
cell
line
import
sinc
envelopedvlp
contain
protein
express
membran
recent
novel
type
vlp
term
chimer
vlp
develop
structur
compos
viral
protein
envelop
protein
deriv
second
viru
recent
porcin
circoviru
type
vlp
develop
display
porcin
reproduct
respiratori
syndrom
viru
epitop
b
open
possibl
use
vlp
deliveri
system
envelop
protein
act
signal
specif
tissu
receptor
way
vlp
may
target
given
tissu
capsid
protein
link
compon
deliveri
target
tissu
thu
vlp
new
applic
drug
deliveri
gene
therapi
cancer
treatment
express
system
chosen
vlp
product
must
take
consider
requir
protein
fold
posttransl
modif
sever
express
system
avail
main
advantag
disadvantag
system
summaris
tabl
bacteria
yeast
repres
easili
scale
costeffect
product
system
bacteria
suitabl
express
system
vlp
form
one
two
structur
protein
envelop
main
advantag
high
yield
protein
interest
howev
bacteria
unabl
perform
posttransl
modif
import
vlp
immunogen
product
hpv
type
vlp
success
carri
use
lactobacillu
casei
immunofluoresc
use
confirm
presenc
conform
epitop
convers
e
coli
bacteria
use
product
recombin
noroviru
capsid
found
use
antigen
also
receptorbind
studi
vaccin
candid
due
abil
yeast
perform
posttransl
modif
repres
step
forward
vlp
product
recent
chikungunya
vlp
produc
use
p
pastori
promis
result
obtain
term
murin
immunis
inde
sever
yeastproduc
vlp
alreadi
reach
approv
regulatori
agenc
papillomaviru
vlp
nevertheless
ptm
pattern
exactli
human
bic
system
process
divid
two
phase
infect
phase
product
phase
baculoviru
design
fast
easi
procedur
make
suitabl
product
vaccin
virus
whose
surfac
protein
vari
outbreak
bic
system
produc
protein
quantiti
compar
achiev
bacteria
yeast
capac
perform
complex
ptm
greater
two
main
insect
cell
line
use
recombin
protein
product
use
bic
express
spodoptera
frugiperda
high
five
cell
trichoplusia
ni
mani
vlp
type
produc
use
bic
system
includ
chikungunya
hiv
porcin
parvoviruslik
particl
main
disadvantag
envelop
baculovirus
also
produc
time
vlp
make
purif
difficult
expens
step
current
platform
produc
vlp
avoid
use
baculoviru
henc
simplifi
purif
stabl
cell
line
gener
protein
interest
continu
express
vlp
produc
stabli
transfect
drosophila
cell
protein
produc
cytotox
effect
regul
induc
promot
transient
transfect
also
carri
insect
cell
cellfectin
use
product
influenza
vlp
consist
haemagglutinin
ha
matrix
protein
cell
littl
research
investig
use
cheaper
transfect
reagent
polyethyleneimin
pei
recombin
protein
product
insect
cell
sever
mammalian
cell
type
suitabl
vlp
product
although
mammalian
cell
produc
less
protein
interest
compar
system
capac
produc
complex
accur
ptm
reason
mammalian
cell
typic
use
produc
complex
envelop
vlp
compos
multipl
structur
protein
sever
mammalian
cell
line
avail
recombin
protein
product
adapt
grow
suspens
use
serumfre
chemic
defin
media
one
extens
utilis
chines
hamster
ovari
cho
cell
line
comparison
mammalian
cell
line
advantag
humanderiv
therefor
present
lower
risk
contamin
human
virus
cho
cell
alreadi
use
gener
hantaviruslik
particl
abl
induc
specif
immun
respons
mice
cell
line
anoth
wide
use
mammalian
product
platform
test
product
mani
differ
type
vlp
rabi
hiv
influenza
human
cell
line
evalu
product
complex
recombin
protein
includ
capt
cell
deriv
human
amniot
fluid
vlp
product
two
method
produc
vlp
mammalian
cell
cultur
classic
method
gener
stabl
cell
line
gene
encod
protein
interest
integr
process
start
transfect
cell
cultur
follow
singl
clone
select
process
high
produc
select
six
month
later
stabl
cell
line
obtain
transient
transfect
much
faster
process
case
vlp
harvest
approxim
h
post
transfect
gener
appreci
quantiti
product
interest
within
two
week
process
suitabl
small
quantiti
differ
vlp
need
initi
research
phase
also
use
wildtyp
antigen
interest
undergo
frequent
mutat
requir
vaccin
frequent
modifi
one
vlp
protein
toxic
produc
cell
line
transgen
plant
also
use
vlp
product
agrobacterium
tumefacien
commonli
use
infect
transform
cell
bacteria
infect
plant
cell
introduc
specif
gene
interest
host
genom
sever
exampl
avail
vlp
product
plant
hpv
type
influenza
commonli
use
plant
recombin
protein
product
nicotiana
tabacum
arabidopsi
thaliana
other
includ
potato
tomato
comparison
product
yield
among
differ
system
alway
straightforward
sinc
product
depend
system
also
complex
vlp
nevertheless
wide
rang
yield
estim
previous
discuss
bacteria
yeast
highconcentr
product
system
yield
vari
mg
protein
per
ml
cultur
animalbas
system
achiev
lower
product
yield
mgml
case
bic
system
mgml
mammalian
cell
technolog
anim
cell
tend
lower
vlpproduc
complex
envelop
vlp
becom
platform
choic
transgen
plant
difficult
compar
system
sinc
product
gener
calcul
per
mg
veget
tissu
yield
rang
pgmg
leaf
vlp
product
three
differ
cultur
mode
batch
fedbatch
continu
cultiv
batch
mode
element
need
ad
begin
cultur
advantag
medium
well
utilis
product
highli
concentr
method
commonli
use
vlp
product
use
mani
type
vlp
includ
hiv
chikungunya
viru
ebola
viru
extend
exponenti
growth
phase
fedbatch
mode
implement
small
quantiti
nutrient
medium
ad
cultur
suppli
cell
specif
compon
deplet
fedbatch
strategi
use
reach
high
cell
concentr
fedbatch
test
product
parvoviruslik
particl
bic
system
final
continu
cultiv
mode
fresh
medium
ad
condit
medium
extract
method
continu
product
obtain
product
must
store
proper
condit
produc
product
concentr
remain
batch
mode
higher
total
quantiti
obtain
howev
continu
product
requir
larg
amount
medium
present
difficulti
adapt
method
largescal
product
recent
novel
product
strategi
term
extend
gene
express
ege
use
mammalian
cell
line
transient
transfect
use
vlp
product
case
cell
medium
renew
everi
h
two
retransfect
round
carri
erlenmey
flask
scale
continu
cultiv
also
use
produc
rabi
vlp
cell
line
made
stabli
express
vlp
bioreactor
scale
fedbatch
continu
cultiv
mode
also
use
gene
encod
vlp
protein
stabli
express
cell
line
platform
regul
induc
promot
attain
high
densiti
cell
growth
gene
express
induc
obtain
higher
protein
concentr
classic
bioreactor
recombin
protein
product
stainless
steel
vessel
nevertheless
singleus
technolog
gain
import
manufactur
biopharmaceut
use
small
medium
scale
product
certain
advantag
vlp
product
requir
situ
clean
sterilis
process
preclud
crosscontamin
report
oper
singleus
bioreactor
reduc
significantli
invest
well
oper
cost
howev
singleus
vessel
less
use
larg
volum
product
maximum
product
volum
l
limit
process
depend
bag
bag
may
also
releas
leachabl
extract
cell
cultur
obtain
limit
factor
product
probe
need
monitor
cultur
also
well
adapt
singleus
technolog
hepat
b
viru
hbv
small
dna
viru
famili
hepadnavirida
approxim
nm
size
compos
lipid
envelop
capsid
contain
viral
circular
dna
genom
kb
dna
polymeras
core
protein
viru
hbcag
code
c
gene
envelop
protein
hbsag
code
gene
viral
genom
first
hbv
vaccin
deriv
inactiv
hbsag
particl
sera
hbvposit
patient
develop
recombin
dna
technolog
safeti
concern
regard
human
plasmaderiv
vaccin
spur
interest
develop
newgener
vaccin
hbsag
initi
produc
e
coli
secret
protein
misfold
eukaryot
cell
line
sought
produc
recombin
protein
yeast
mammalian
cell
two
system
use
product
hbv
vaccin
yeast
line
stabli
express
envelop
protein
hbsag
selfassembl
secret
yeast
cell
result
nm
size
particl
similar
produc
infect
human
cell
mammalian
cho
cell
line
also
use
product
hbsag
vlp
tend
larger
one
produc
yeast
compos
mixtur
glycosyl
nonglycosyl
hbsag
contrast
yeast
vlp
compos
nonglycosyl
hbsag
differ
size
composit
lead
higher
immunogen
particl
vaccin
also
produc
variou
transgen
plant
hepat
e
vlp
vaccin
also
approv
china
name
hecolin
capsid
protein
hepat
e
express
e
coli
purifi
hek
protein
selfassembl
homodim
result
format
vlp
vlpbase
hepat
c
vaccin
also
current
research
stage
rt
mosquirix
first
vaccin
gener
parasit
diseas
vlpbase
vaccin
compos
surfac
hepat
b
viru
part
secret
circumsporozoit
protein
csp
malaria
parasit
central
tandem
repeat
r
epitop
csp
carboxytermin
three
part
rt
engin
hepat
b
surfac
antigen
hbsag
upon
express
yeast
cell
fusion
protein
form
vlp
present
antigen
immun
system
thu
provok
respons
vlp
vaccin
hpv
base
structur
capsid
protein
two
avail
vaccin
hpv
prevent
gardasil
cervarix
protect
hpv
type
cancerassoci
serotyp
gardasil
vlp
produc
cerevisia
protect
hpv
type
recombin
protein
abil
selfassembl
insid
yeast
form
vlp
purifi
cell
disrupt
process
carri
follow
seri
chemic
physic
purif
step
cervarix
produc
trichoplusia
ni
cell
infect
recombin
baculoviru
contain
gene
cell
disrupt
process
follow
sever
purif
step
obtain
protein
purif
process
assembl
vlp
also
hpv
vlp
protect
hpv
type
produc
yeast
even
bacteria
research
stage
influenzaviru
nanomet
diamet
envelop
compos
two
protein
hemagglutinin
ha
neuraminidas
na
commonli
target
protein
antivir
treatment
bic
platform
use
product
influenza
vlp
cell
infect
use
three
differ
baculovirus
baculoviru
encod
one
gene
ha
na
matrix
protein
gene
coexpress
three
protein
lead
format
vlp
harvest
cultur
supernat
vlp
provid
broader
immun
respons
inactiv
viru
recombinantli
produc
hemagglutinin
transgen
plant
technolog
also
use
product
influenza
vlp
provid
good
result
preclin
phase
complet
hiv
particl
measur
approxim
nm
genom
contain
major
gene
gag
pol
env
gag
encod
three
domain
capsid
virion
specif
matrix
subdomain
bind
inner
phase
lipid
envelop
surround
particl
capsid
ca
domain
form
conic
condens
core
contain
viral
rna
bound
nucleocapsid
nc
domain
viral
enzym
envelop
protein
encod
env
gene
place
lipid
bilay
display
viral
surfac
final
pol
encod
enzymat
protein
involv
viral
cycl
hiv
vlp
produc
use
differ
express
platform
express
gag
polyprotein
abil
migrat
cell
membran
selfassembl
bud
cell
hiv
vlp
produc
cerevisia
alreadi
reach
clinic
trial
phase
compos
structur
protein
among
mammalian
cell
line
use
product
hiv
vlp
base
gag
andor
env
protein
use
either
transient
transfect
gener
stabl
cell
line
insect
cell
baculoviru
system
also
use
product
gagenv
vlp
stabl
insect
cell
line
produc
gag
polyprotein
develop
express
vlp
human
parvoviru
small
nonenvelop
dna
viru
famili
parvovirida
two
main
structur
protein
human
parvoviru
vlp
reach
clinic
trial
stage
compos
protein
produc
bic
system
cell
infect
two
baculovirus
lead
product
selfassembl
immunogen
vlp
noroviru
nv
rna
viru
respons
acut
viral
gastroenter
belong
calicivirida
nonenvelop
kb
genom
encod
larg
polyprotein
cleav
structur
regulatori
protein
nv
vlp
clinic
trial
compos
capsid
protein
main
structur
protein
express
bic
system
produc
promis
result
clinic
trial
nv
vlp
form
capsid
protein
also
produc
transgen
plant
clinic
trial
level
sever
acut
respiratori
syndromerel
coronaviru
sarscov
sarscov
belong
coronavirida
envelop
unusu
larg
kb
singlestrand
rna
genom
encod
proteinswhich
either
regulatori
structur
role
viru
compos
four
structur
protein
nucleocapsid
np
spike
sp
membran
mp
envelop
ep
also
produc
bic
system
cell
express
sp
ep
mp
infect
cultur
three
differ
baculovirus
one
per
protein
express
research
level
viruslik
particl
repres
step
forward
vaccin
develop
resembl
actual
structur
viru
provok
humor
cellular
immun
respons
furthermor
contain
viral
genet
materi
make
safer
vaccin
recipi
oper
contact
vaccin
advantag
compar
classic
vaccin
liveattenu
inactiv
danger
accident
infect
bacteria
yeast
easi
fast
platform
recombin
protein
product
lack
abil
produc
complex
structur
ptm
make
suitabl
product
simpl
gener
nonenvelop
vlp
bic
system
abil
produc
much
complex
structur
due
abil
glycosyl
recombin
protein
system
reach
high
yield
compar
obtain
bacteria
yeast
baculoviru
design
construct
cell
infect
also
rel
straightforward
process
streamlin
product
main
drawback
platform
purif
step
envelop
baculovirus
produc
time
vlp
possess
similar
physic
chemic
characterist
reason
baculovirusfre
system
use
insect
cell
current
investig
final
mammalian
cell
suitabl
product
complex
structur
system
faith
replic
human
glycosyl
pattern
repres
signific
advantag
howev
yield
obtain
mammalian
cell
line
gener
much
lower
compar
system
select
produc
cell
line
must
consid
need
characterist
vlp
produc
especi
import
step
envelop
vlp
product
sinc
membran
protein
produc
cell
line
present
vlp
envelop
possibl
enhanc
immunogen
act
adjuv
number
vlpbase
vaccin
alreadi
avail
market
good
result
mani
other
still
clinic
preclin
trial
interest
vlp
design
product
increas
recent
year
due
advantag
present
classic
vaccin
new
applic
cell
line
target
drug
deliveri
explor
open
possibl
new
use
vlp
technolog
